Eyemate : Study Highlights Importance Of Continual IOP Monitoring For Glaucoma
Currently glaucoma patients are getting (2-6) visits per year in a doctor’s office. It puts patients at high risk of undetected disease progression. Clinical study published recently, shows EYEMATE TM system is safe, reliable and monitor IOP continuously without regular office visits. The FDA “Breakthrough Device” approval process has been started, in preparation for launching it in the USA. The CE-marked EYEMATE system is now offered in Germany, Switzarland and the UK. Prof. Kaweh Mansouri, lead author of the study and ophthalmologist at Clinique de Montchoisi Lausanne/Switzerland, explains: “Our findings show that occasional IOP measurements, as are currently done in clinical practice, poorly reflect actual IOP behavior in patients. These data underline the importance of continual IOP monitoring for better management of glaucoma care.”
For more information: https://www.b3cnewswire.com/